相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications
Daniel J. Drucker
ENDOCRINE REVIEWS (2020)
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease
Yoshimasa Aso et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2019)
Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition
Elodie M. Varin et al.
CELL METABOLISM (2019)
A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection
Michael P. Dube et al.
CLINICAL INFECTIOUS DISEASES (2019)
Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo-controlled study
J. Koska et al.
DIABETIC MEDICINE (2019)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage
Mickael J. Ploquin et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2018)
DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice
Takeshi Kawasaki et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4
A. Casrouge et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4
Kumiko Kaifu et al.
MICROVASCULAR RESEARCH (2018)
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
Devram S. Ghorpade et al.
NATURE (2018)
Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis
M. Salaga et al.
PEPTIDES (2018)
Hepatic DPP4 DNA Methylation Associates With Fatty Liver
Christian Baumeier et al.
DIABETES (2017)
Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II-Induced Cardiac Diastolic Dysfunction in Male Mice
Scott M. Brown et al.
ENDOCRINOLOGY (2017)
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Allison B. Goldfine et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Inflammatory mechanisms linking obesity and metabolic disease
Alan R. Saltiel et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes
Titli Nargis et al.
MOLECULAR METABOLISM (2017)
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
Christian Baumeier et al.
MOLECULAR METABOLISM (2017)
Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes
Julie A. Lovshin et al.
DIABETES CARE (2017)
Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis
Erin E. Mulvihill et al.
CELL METABOLISM (2017)
Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice
Erin E. Mulvihill et al.
DIABETES (2016)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
C. Klemann et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
Yochai Birnbaum et al.
BMJ OPEN DIABETES RESEARCH & CARE (2016)
GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
Jacqueline A. Koehler et al.
CELL METABOLISM (2015)
GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
Bernardo Yusta et al.
DIABETES (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects
Radwan H. Ahmed et al.
PLOS ONE (2015)
Dipeptidyl-Peptidase-4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low-Density Lipoprotein (LDL) Receptor- Deficient Mice
Koji Akita et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2
Nina Wronkowitz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Cardiovascular Actions of Incretin-Based Therapies
John R. Ussher et al.
CIRCULATION RESEARCH (2014)
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill et al.
ENDOCRINE REVIEWS (2014)
Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes
Andre J. Tremblay et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
Soluble DPP4 originates in part from bone marrow cells and not from the kidney
Zhendi Wang et al.
PEPTIDES (2014)
A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation
Jixin Zhong et al.
DIABETES (2013)
Adipose Dipeptidyl Peptidase-4 and Obesity Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro
Henrike Sell et al.
DIABETES CARE (2013)
Variations in Inflammatory Biomarkers Following the Addition of Sitagliptin in Patients with Type 2 Diabetes not Controlled with Metformin
Giuseppe Derosa et al.
INTERNAL MEDICINE (2013)
CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
Sang Ah Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune or Virological Status in HIV Infected Men And Women: A Pilot Safety Study
Scott R. Goodwin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj et al.
NATURE (2013)
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
Noriko Satoh-Asahara et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis
Shunya Mimura et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes Role of dipeptidyl peptidase-IV inhibition
Maria Rosaria Rizzo et al.
DIABETES CARE (2012)
Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats
Atul Sureshrao Akarte et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Sitagliptin Exerts an Antinflammatory Action
Antoine Makdissi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Daniela Lamers et al.
DIABETES (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
E. M. Migoya et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes - Preclinical biology and mechanisms of action
Daniel J. Drucker
DIABETES CARE (2007)
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1
Brian D. Green et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
(2S, 3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl4-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide:: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Scott D. Edmondson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors
T Hansotia et al.
DIABETES (2004)
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
JM Lenhard et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
B Ahrén et al.
DIABETES CARE (2002)
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
D Marguet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
